Abstract: The present invention provides an agent for inducing regression of triglyceride (TG) deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, an agent for improving blood flow in a patient with TG deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, and a pharmaceutical or food or drink product comprising the agent for inducing regression of TG deposit atherosclerosis or the agent for improving blood flow.

Abstract: A brain image analysis apparatus (2000) acquires input data (40) including a structural brain image (42) and a functional brain image (44) for a subject (10). The brain image analysis apparatus (2000) obtains analysis data (20) by inputting the input data (40) into an analysis model (2020). The analysis model (2020) has been trained in advance so as to output the analysis data (20) representing information about brain dysfunction in response to an input of the input data (40). The brain image analysis apparatus (2000) outputs, based on the analysis data (20), output data (30) representing information about the brain dysfunction of the subject (10).

Abstract: The computer implemented method makes it possible to discern, for a variety of sensations, whether a sensation is a pleasant (comfortable) sensation or a sensation of discomfort. A classifier is generated for discerning the stress or comfort/discomfort of a subject. The method comprising: a) imparting, to a subject, different stimuli under the same environment, and obtaining brain wave data or analysis data thereof for the environment; b) correlating a reaction of the subject relating to the stimulation and the difference of the brain wave data or analysis data thereof obtained under the environment; c) generating a classifier for discerning the stress or comfort/discomfort of the subject, on the basis of the correlation; and d) performing comfort/discomfort discernment using a basic step for amplifying a sample from a small stimulation.

Abstract: The present invention relates to a gel composition containing at least one selected from the group consisting of an extracellular matrix component and a fragmented extracellular matrix component, and an ion of a metal element.

Abstract: The present invention provides a gel formed of fibrin and a molecule generated by thrombin treatment of a chimeric protein that comprises a fibrinogen fragment capable of binding to fibrinogen upon thrombin treatment and a laminin fragment having integrin-binding activity, and optionally further comprises a protein having growth factor-binding activity. The gel of the present invention is suitable as a gel substrate that has properties of the basement membrane and can be used in medical applications.

Abstract: The invention provides a method for producing a solution containing 211At? (astatide ion) at a high radiochemical purity by using 211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from 211At. The invention also provides a solution containing 211At? (astatide ion) at a radiochemical purity of not less than 30%.

Abstract: A non-transitory computer-readable recording medium stores therein an information processing program that causes a computer to execute a process including, deciding on one or more variables, from among a plurality of variables, to be a target for a question regarding degree of importance, based on order of priority of the variables and estimated amount, the order of priority of the variables being determined based on a plurality of patterns indicating ranking of the plurality of variables, the estimated amount indicating possibility of a match with predetermined condition regarding each of the patterns, and updating the estimated amount based on an answer result of the question about the decided variable.

Abstract: Provided is a novel agent capable of binding to a CUG repeat sequence. The agent comprises a compound A having a binding response of 10 resonance units (RU) or more at 25 nM to a (CUG)9 RNA immobilized at 401 RU as determined by surface plasmon resonance.

Abstract: An information processing device classifies a plurality of linear models, each of which includes one or more variables, into a plurality of groups in such a way that the linear models which include identical variables included in each of the plurality of linear models and which have identical coefficient encoding with respect to the variables are grouped in the same group, outputs a first question used in deciding degree of importance of each explanatory variable included in training data which is used in training of the plurality of linear models, and, decides on an explanatory variable about which a second question is to be asked, when a linear model in which the degree of importance is reflected is to be selected from the plurality of linear models, based on extent of decrease in number of target groups for selection according to an answer to the first question.

Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

Abstract: A tube assembly for a living organism includes a tube and a first ferrule. The tube is partially placeable into a living organism. The tube includes a first end, a second end, a through-hole, and a lens. The through-hole extends in a first direction from the second end to the first end. The first ferrule covers an outer periphery of the tube in the first direction. The lens is located in a portion of the through-hole including at least the first end. The tube and the first ferrule contain a ceramic material.

Abstract: Provided is a method for producing, from a carboxylic acid ester, a corresponding ether. In the method, the reaction product and catalyst can be easily separated, and a large amount of salt waste or hazardous waste is not discharged. The method for producing an ether includes reducing a carboxylic acid ester with molecular hydrogen in the presence of the following Catalyst and producing the corresponding ether, in which the —C(?O)O— group of the carboxylic acid ester has been converted to a —CH2O— group: Catalyst: a catalyst in which the following M1 and M2 are supported as metal species on the following Support. M1: platinum, ruthenium, rhodium, palladium, or iridium. M2: molybdenum, rhenium, tungsten, or vanadium. Support: zirconium oxide, titanium oxide, cerium oxide, or hydroxyapatite.

Abstract: This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.

Abstract: According to one embodiment, a nitride crystal includes first, second, and third nitride crystal regions. The third nitride crystal region includes Al, and is provided between the first and second nitride crystal regions. A third oxygen concentration in the third nitride crystal region is greater than a first oxygen concentration in the first nitride crystal region and greater than a second oxygen concentration in the second nitride crystal region. A third carbon concentration in the third nitride crystal region is greater than a first carbon concentration in the first nitride crystal region and greater than a second carbon concentration in the second nitride crystal region. A <0001> direction of the first nitride crystal region is one of a first orientation from the second nitride crystal region toward the first nitride crystal region or a second orientation from the first nitride crystal region toward the second nitride crystal region.

Abstract: Methods of treating diseases caused by repeat DNA instability are described herein. The methods described herein can inhibit the further expansion of repeat DNA and, in some instances, reduce the size of the repeat DNA (e.g., reduce the number of repeats).

Abstract: A liquid crystal element is provided that can inhibit occurrence of voltage drop between one end and the other end of each electrode. A liquid crystal element (100) includes a liquid crystal layer LQ, a plurality of first arcuate electrodes (1), and a plurality of second arcuate electrodes (2). The first arcuate electrodes (1) are disposed concentrically about an optical axis (AX) of the liquid crystal element (100) and applies first voltage (V1) to the liquid crystal layer (LQ). The second arcuate electrodes (2) are disposed concentrically about the optical axis (AX) and applies second voltage (V2) to the liquid crystal layer (LQ).

Abstract: A tracheal connector is connected to a respiratory gas generator and a tracheal tube. The tracheal connector includes a tracheal connector body connected to the tracheal tube, a connector tube connected to the tracheal connector body and the respiratory gas generator, and a restriction mechanism configured to narrow a respiratory gas flow path configured to allow the respiratory gas to flow therein. The tracheal connector body includes a tracheal port connected to the tracheal tube, an exhaust port facing the tracheal port and configured to discharge at least expired air of the subject, and a respiratory port connected to the connector tube. The restriction mechanism is provided on the respiratory gas flow path between the respiratory port and the tracheal port.

Abstract: A multicopter system according to one aspect of the present invention includes a multicopter configured to fly in a state of holding a package and a mooring device that is installed at a target position of a flight of the multicopter and includes a linear member that extends in a predetermined direction from the target position, the multicopter including a reception portion that has the shape of a recess including an opening open toward one direction and is configured to receive the linear member via the opening.

Abstract: It is an object to provide a combination therapy effective in cancer immunotherapy. The object is achieved by providing an anti-tumor agent, including a transformed Bifidobacterium containing DNA encoding a WT1 protein and DNA encoding a GNB/LNB substrate-binding membrane protein derived from a Bifidobacterium, the transformed Bifidobacterium being designed to display the WT1 protein as an antigen on a surface of the transformed Bifidobacterium, the anti-tumor agent being for use in combination with an immunosuppression inhibitor. The transformed Bifidobacterium can be used as an oral tumor vaccine.

Abstract: Provided is a laminated body that has high adhesiveness between a resin body containing a fluorine-based resin and a silicone gel and that can be attached to and detached from an adherend for use. A laminated body comprising: a resin body; and a gel body, wherein the resin body comprises a fluorine-based resin, and the gel body comprises a silicone gel and lipophilic silica particles.